Latest / UK Column Radio / David Rasnick on the AIDS and Cancer Hoax | Jerm Warfare
Transcript
- 0:30Speaker 1: My name is June. This is Jim Wolfe The Battle
- 0:33Speaker 1: of Ideas.
- 0:35Speaker 2: I have a PhD in chemistry and undergraduate degrees in
- 0:38Speaker 2: biology and chemistry, and I worked in the pharmaceutical biotech
- 0:43Speaker 2: field for about twenty years. And it was one of
- 0:48Speaker 2: two brand new PhD chemists that Habit Laboratories hired in
- 0:53Speaker 2: nineteen seventy eight to set up the chemistry group and
- 0:56Speaker 2: the diagnostics division, and we did that. I left in
- 1:03Speaker 2: nineteen eighty. I left Abbot to start my first biotech
- 1:10Speaker 2: company in California. Moved Insime Systems Products, had that for
- 1:13Speaker 2: about ten years, spun it off into I think it
- 1:18Speaker 2: was Prototech. I can't remember all the names now, and
- 1:23Speaker 2: then eventually I left the pharmaceutical industry for good in
- 1:28Speaker 2: nineteen ninety six. And it had to do primarily with
- 1:32Speaker 2: what I had seen when I first started at Abbot.
- 1:36Speaker 2: One of the vice presidents in the room full of
- 1:38Speaker 2: maybe fifteen ephds or whatever, was saying he was thinking
- 1:43Speaker 2: about not running an FDA clinical trial for one of
- 1:47Speaker 2: the things they were going to market. And he said
- 1:50Speaker 2: that right in this room full of all of us,
- 1:53Speaker 2: and one of the other executives said, John, I don't
- 1:55Speaker 2: know what the guy's name, but let's say it was John.
- 1:58Speaker 2: He said, John, Now we can't do that because he
- 2:00Speaker 2: knew that he shouldn't have been saying that to the audience,
- 2:03Speaker 2: all right, So that struck me immediately, obviously, you know,
- 2:09Speaker 2: to see the interaction. But then I just left it alone.
- 2:13Speaker 2: I only remembered it years later when I saw other
- 2:16Speaker 2: things similar like that and experienced what was going on.
- 2:21Speaker 2: And then what really changed me was in the nineteen eighties,
- 2:25Speaker 2: mid nineteen eighties with the AID stuff, and because I
- 2:30Speaker 2: just moved to San Francisco at nineteen eighties San Francisco
- 2:33Speaker 2: Bay Area, of course that's when the AIDS thing started happening,
- 2:37Speaker 2: but it wouldn't call that. It's called GRID, gay related
- 2:40Speaker 2: immune deficiency at the time. And what a lot of
- 2:43Speaker 2: people don't know, and I only learned about it later,
- 2:47Speaker 2: working before I met with Peter. Though. Digging into this
- 2:50Speaker 2: AID stuff is that the CDC actually knew as early
- 2:54Speaker 2: as nineteen eighty two that GRID gave related immune deficiency
- 2:59Speaker 2: which later was to AIDS. Was the use of chronic
- 3:04Speaker 2: use of recreational drugs among gay men in the nightclubs
- 3:08Speaker 2: that Amal of Beutal nitrites, and those are carcinogenic chemicals.
- 3:12Speaker 2: I wouldn't open a bottle of that stuff outside of
- 3:15Speaker 2: a fume hood. And these guys had it in the
- 3:18Speaker 2: atmosphere in their nightclubs, and you could see it was
- 3:21Speaker 2: like cigarette smoke. You see videos of it, you know
- 3:25Speaker 2: of that. So people should not be surprised that they
- 3:28Speaker 2: had these horrible things happened to them. And so that
- 3:35Speaker 2: was that and then old on.
- 3:38Speaker 1: So that drug. Are you referring to poppers?
- 3:41Speaker 2: Yeah, puppers. I used the chemical names. Sorry about that
- 3:46Speaker 2: amal of beutal nitrite with the poppers, you know. And
- 3:48Speaker 2: the CDC understood this as earliest nineteen eighty two, but
- 3:52Speaker 2: I didn't learn about that until the later eighties, you know,
- 3:57Speaker 2: because I didn't know all this shenanigans and things that
- 4:00Speaker 2: were going on. Then in nineteen eighty four, April twenty third,
- 4:03Speaker 2: nineteen eighty four, the world changed. Margaret Heckler, the Secretary
- 4:08Speaker 2: of Health and Human Services, called Robert Gallo out there
- 4:12Speaker 2: that he had discovered the probable cause of AIDS. It
- 4:15Speaker 2: was one of his HTLV viruses. He called it HTLV three.
- 4:19Speaker 2: Later it was changed to HIV. And I didn't know it.
- 4:24Speaker 2: At that time, I assumed, Okay, there's a lot going
- 4:26Speaker 2: on here, so I'm a chemist. Aha, a retrovirus this thing,
- 4:31Speaker 2: and I knew viruses. They have all these different genes
- 4:36Speaker 2: and almost all of them have a proteace, and I
- 4:38Speaker 2: was expertal proteations, so I wanted to know what kind
- 4:41Speaker 2: of proteations these retroviruses have spartal proteas, so that I
- 4:45Speaker 2: had worked on sparal proteases up to that point, but
- 4:48Speaker 2: I immediately wanted to start designing inhibitors for spartal proteace
- 4:52Speaker 2: to cure AIDS. You know, this is nineteen eighty four.
- 4:55Speaker 2: That's what went through my mind, that the young chemist
- 4:57Speaker 2: was my own company and everything. But I got it
- 5:02Speaker 2: was probably three or four months. So I dropped the
- 5:05Speaker 2: whole effort because I knew that Abbot had been working
- 5:11Speaker 2: on a spartal proteation hipters for some years and there's
- 5:15Speaker 2: no way I could catch up with that with my
- 5:17Speaker 2: small little company in them. They probably already had someone
- 5:20Speaker 2: on the shelf that they would probably be trying. And
- 5:22Speaker 2: oddly enough, I met up with one of the guys
- 5:24Speaker 2: at Abbot in the early nineteen nineties. I asked him,
- 5:27Speaker 2: how many spartal protation hippnters did you have in twenty
- 5:30Speaker 2: twenty four he said three thousand. I was aft mating two.
- 5:35Speaker 2: So you said, it was a smart move on my
- 5:37Speaker 2: part to drop that entirely. But I still went along
- 5:41Speaker 2: with it, you know, And it was the whole thing.
- 5:47Speaker 2: And one of the things this another thing that really
- 5:51Speaker 2: struck me profoundly was I think it was it was
- 5:55Speaker 2: eighty four eighty five. Was nineteen eighty five when we
- 5:59Speaker 2: learned about this contagious disease, the viruses causing it and everything,
- 6:04Speaker 2: And then it was very clear it had been going
- 6:06Speaker 2: on for several years. And here it was in the
- 6:09Speaker 2: Bay Area and AIDS AIDS was in the gay community primarily,
- 6:14Speaker 2: you know, it didn't cross the street in the Castro
- 6:17Speaker 2: District district, and the gay men got keposisar coma, and
- 6:23Speaker 2: the heterosexual didn't get kepos sarcoma. They had other things
- 6:28Speaker 2: and so and women didn't get it at all, you know.
- 6:31Speaker 2: And so nine out of ten AIDS cases were male.
- 6:37Speaker 2: You know, here we've had this supposedly sexually transmitted contagious
- 6:41Speaker 2: thing going on for six years, you know, and and
- 6:46Speaker 2: it was not behaving like a transmissible disease. That was
- 6:50Speaker 2: the thing. It was not behaving like a transmissible disease.
- 6:54Speaker 2: And so I brought this up once a month a
- 6:58Speaker 2: group of US academics, industrial people, a biotech people, pharmaceutical
- 7:05Speaker 2: people like nin Tech and my little company and others.
- 7:08Speaker 2: We'd meet once a month at University of California, San
- 7:11Speaker 2: Francisco for a little seminar, and then after that we
- 7:15Speaker 2: would go to the same Chinese restaurant. Was really good
- 7:19Speaker 2: every time where we got together. And that's that was
- 7:22Speaker 2: really why a lot of us went. Not for the seminars,
- 7:24Speaker 2: they're pretty boring, but then we would get to talk
- 7:27Speaker 2: to each other, learn about each other, what we're doing,
- 7:30Speaker 2: and set up the occasional collaboration. And I set up
- 7:35Speaker 2: a really nice one was a guy who was working
- 7:37Speaker 2: with parasites in animals and from one of those get togethers,
- 7:46Speaker 2: and so it was a nice thing to do. And
- 7:51Speaker 2: then I brought to you know, like me, you we talked,
- 7:54Speaker 2: scientists talk a lot, you know, share these things. That's
- 7:57Speaker 2: why we went to those meetings. And when I I
- 8:00Speaker 2: told them the AIDS, I said, I look like it's
- 8:02Speaker 2: this contagious disease. Nobody would talk to me all these
- 8:07Speaker 2: people I've been talking to for some years, you know,
- 8:10Speaker 2: and we would be sharing things. And boy, that struck
- 8:14Speaker 2: me that, you know, what's wrong here? And I was
- 8:17Speaker 2: able to keep the collaboration with that academic fellow on
- 8:22Speaker 2: this one thing that we had already been working on.
- 8:26Speaker 2: If we both agreed not to talk about AIDS. That's
- 8:29Speaker 2: how I was able to keep a collaboration going, you know.
- 8:33Speaker 2: And that was a very very that hit me really hard.
- 8:36Speaker 2: So then I went to bookstores, the gay community, the
- 8:40Speaker 2: Castro they have all these bookstores, massive bookstores. Of course, AIDS.
- 8:44Speaker 2: They had in the bookstores, massive collection of books on AIDS.
- 8:48Speaker 2: So I got those and I read those things, and
- 8:52Speaker 2: I was learning about it, you know. And then and
- 8:57Speaker 2: in nineteen eighty seven, of course, that's when Peter Deusberg
- 9:02Speaker 2: wrote and invited a paper in cancer Research in nineteen
- 9:05Speaker 2: eighty seven. I didn't see it in eighty seven. I
- 9:07Speaker 2: saw it probably the year later, and where he was
- 9:11Speaker 2: the world's leading authority on retroviruses and HIV supposedly a retrovirus,
- 9:17Speaker 2: and it was like a legal document, point for point
- 9:19Speaker 2: for point for point, how retroviruses in general and HIV
- 9:23Speaker 2: in particular cannot cause any disease at all. And Peter
- 9:28Speaker 2: Dusburg had been doing this and saying this for years,
- 9:32Speaker 2: you know, in the eighties, and he continued doing it
- 9:35Speaker 2: in the nineties. And right after that nineteen eighty seven
- 9:40Speaker 2: paper it was, I think it was nineteen eighty seven, Yeah,
- 9:43Speaker 2: it was nineteen eighty seven in cancer research, he had
- 9:47Speaker 2: the Outstanding Investigator grant. You know, he was a tenured professor.
- 9:51Speaker 2: He probably would have gotten a Nobel Prize at some point,
- 9:55Speaker 2: but right after that paper, his grants, his government funding
- 9:59Speaker 2: was stopped, and he had Outstanding Investigator him. I think
- 10:02Speaker 2: you were able to keep it for seven years with
- 10:05Speaker 2: having to reknew it or something like that. And so
- 10:09Speaker 2: that was another thing. Now, I didn't know about Peter
- 10:13Speaker 2: Dusburg personally until I got to meet him in nineteen
- 10:17Speaker 2: ninety three. I went across the bay and I got
- 10:20Speaker 2: to see him, and Carrie Mollis was there, so he
- 10:23Speaker 2: introduced me to Carry Mollis, the guy invented primrace chain reaction.
- 10:29Speaker 2: But then I kept going back to my little companies,
- 10:33Speaker 2: you know, and doing my own things. But I just
- 10:34Speaker 2: wanted to meet the guy, and I had my fill
- 10:39Speaker 2: of the biotech pharmaceutical industry in nineteen ninety six and
- 10:45Speaker 2: I just left for good and I went across the
- 10:50Speaker 2: Bay to join up with Peter. I wanted help him,
- 10:54Speaker 2: support him. I thought maybe for three or four months.
- 10:56Speaker 2: So we did it for years, almost two decades. And
- 11:02Speaker 2: I tell you you know, he died recently in January, unfortunately.
- 11:06Speaker 2: And Joan Shenton is making a movie about the other
- 11:10Speaker 2: people are too HD Children's Health Defense. They're they're they're
- 11:14Speaker 2: promoting this, telling this story, and so h that was
- 11:20Speaker 2: when Peter Dusburg and I joined up and we worked
- 11:25Speaker 2: alternately on AIDS and cancer, AIDS and cancer and it
- 11:29Speaker 2: was h I think it was nineteen ninety seven. He
- 11:33Speaker 2: had no more fun he had. He had some individual
- 11:36Speaker 2: rich people in the Bay area who was fund who
- 11:38Speaker 2: were funding his lab because he couldn't get government funny
- 11:41Speaker 2: for it. Not nearly as much money as the government
- 11:43Speaker 2: was paying though, but it kept his lab going. But
- 11:45Speaker 2: it was really shrunk down his side, and so Peter
- 11:50Speaker 2: finally started. We went to a little coffee shop about
- 11:55Speaker 2: a few days maybe a week before he went to Germany.
- 11:58Speaker 2: It was across from the campus, and we were talking
- 12:01Speaker 2: about things, And I asked, Peter, what are you going
- 12:02Speaker 2: to be doing in Germany and the Sabattle And then
- 12:07Speaker 2: he told me he was going to look into the
- 12:10Speaker 2: hypothesis that unbounced chromosomes caused cancer because the unbounced chromosomes
- 12:16Speaker 2: called anuploidy. The connection between anuploidy and cancer went all
- 12:20Speaker 2: the way back to the late eighteen hundreds. David Hansoman,
- 12:25Speaker 2: who looked at over ten thousand cancer cells with high
- 12:29Speaker 2: quality microscopes in late eighteen hundreds. He took pictures of them,
- 12:33Speaker 2: He drew pictures of them, and he was very familiar
- 12:38Speaker 2: with the normal cells, and then he looked at the
- 12:40Speaker 2: cancer cells. Normal cells of the same type always looked
- 12:43Speaker 2: the same and they always have the same chromosomes, and
- 12:48Speaker 2: the cancer cells all looked different. No, two cancer cells
- 12:52Speaker 2: had the same combination of chromosomes in over ten thousand
- 12:56Speaker 2: tumors that he looked at cancer cells, I mean cancer
- 12:58Speaker 2: cells that were that he had under the microscope, and
- 13:02Speaker 2: that has been confirmed since then. No two can't. They're
- 13:06Speaker 2: like snowflakes. No, it's like playing a game of chess.
- 13:10Speaker 2: There's no to people that are really really good at chess,
- 13:13Speaker 2: you know, No two chess games have ever been played
- 13:17Speaker 2: exactly the same because of combinations are just so large.
- 13:22Speaker 2: So Peter was going. And then there was theod Boveri,
- 13:25Speaker 2: who knew a lot about self and he understood he
- 13:28Speaker 2: was an expert at development, like from a fertilized egg
- 13:33Speaker 2: going to a person, going to a mouse, going to
- 13:37Speaker 2: amphibian or whatever. He was good in following this progression
- 13:41Speaker 2: of things, and he understood chromosomes too. Nobody knew what
- 13:45Speaker 2: chromosomes were in those days, other than they hypothesized that
- 13:51Speaker 2: they watched the dividing and they always had equal number
- 13:53Speaker 2: that go from when the normal cell divides, they have
- 13:57Speaker 2: an equal number of chromosomes going into the two new cells.
- 14:01Speaker 2: And so they had a pretty good idea. They had
- 14:04Speaker 2: a hypothesis that the instructions you know, these cells used
- 14:10Speaker 2: are in those chromosomes. But they didn't know about DNA,
- 14:12Speaker 2: and they didn't really know about genes in those days.
- 14:16Speaker 2: But they did hypothesize they had to do with developing
- 14:20Speaker 2: of these eggs, and he did a number of experiments.
- 14:23Speaker 2: In fact, if people, I highly recommend your viewers to
- 14:28Speaker 2: go to my website David Rasnick dot com. I have
- 14:32Speaker 2: forty years worth of information on there. And if you
- 14:35Speaker 2: click at the top one cancer, you can go to
- 14:37Speaker 2: the cancer area. We got the aid stuff cancer, and
- 14:41Speaker 2: you go to the cancer area, you'll see a picture
- 14:43Speaker 2: of David Hanson, and you click on that you'll get
- 14:45Speaker 2: a biography of him. You go to Theodore Bovari, you
- 14:49Speaker 2: click on his image, you'll get his fifty nine page
- 14:52Speaker 2: book which spells out you got it right, and it's
- 14:56Speaker 2: in plain language. He by understands English can follow this
- 15:00Speaker 2: and get it how the progression of unbalanced chromosomes can
- 15:06Speaker 2: explain virtually everything about cancer. Now, this was his hypothesis,
- 15:11Speaker 2: and he published this book in nineteen fourteen, and he
- 15:14Speaker 2: died in nineteen fifteen unfortunately, and of course World War
- 15:18Speaker 2: One started in nineteen fourteen Ovari's death, so he's not
- 15:22Speaker 2: around then. He had the Second World War. So his
- 15:27Speaker 2: hypothesis or his theory, frankly, I would call it a
- 15:31Speaker 2: theory and discuss the difference than those if you want later.
- 15:35Speaker 2: And so it never took off. But other people during
- 15:38Speaker 2: that time that didn't even know about Bavari, they had
- 15:41Speaker 2: witnessed very similar things that came up with their own.
- 15:44Speaker 2: Two or three people did, including George Papernicolau papsmir fame,
- 15:48Speaker 2: and he didn't come up with a theory, but he
- 15:50Speaker 2: came up with the Papsmiria, an automated machine to actually
- 15:56Speaker 2: diagnose cancer by counting the chromosomes in the tumor cells.
- 16:03Speaker 2: It never went anywhere, and that's a real pity because
- 16:06Speaker 2: he got it up in working. But so anyway, what
- 16:10Speaker 2: really changed things that long period of two wars and everything.
- 16:15Speaker 2: And then nineteen fifty three Watson and Crick discovered the
- 16:18Speaker 2: double helical structure of DNA, and of course everybody got
- 16:23Speaker 2: all excited. I remember even when that came out. Even
- 16:25Speaker 2: I got excited about Wow, DNA's double helical structure of stuff.
- 16:30Speaker 2: And I was not very old at those days. I'm
- 16:33Speaker 2: just a kid. But as a chemist, I can understand
- 16:39Speaker 2: how other people like me that make molecules and this
- 16:43Speaker 2: molecules that they get really excited about it. Boy, and
- 16:46Speaker 2: now I want to understand this thing. And the genes
- 16:49Speaker 2: are in there, you know, and that's that's where all
- 16:52Speaker 2: the information comes from. And they knew that cancer cells
- 16:59Speaker 2: were annually. They were not stupid about this. They knew
- 17:02Speaker 2: their any plot. But they couldn't understand they were not
- 17:05Speaker 2: thinking about that how that imbalance and chromosomes would leave
- 17:08Speaker 2: to cancer. They were now thinking in terms of molecules
- 17:11Speaker 2: and genes because they have the DNA molecule, and from
- 17:15Speaker 2: that time on the pharmaceutical industry, which makes molecules, synthesizing patents,
- 17:20Speaker 2: molecules are patentable. Then from that day to this day,
- 17:25Speaker 2: you know that whole industry is drug based, synthetic drug based,
- 17:31Speaker 2: and so in order to have a drug for something,
- 17:35Speaker 2: they had to have a target for it. So they're
- 17:38Speaker 2: saying that these gene products on the on the DNA
- 17:42Speaker 2: gets mutated, you know, and the DNA codes for proteins,
- 17:46Speaker 2: primarily my little things that I worked with a lot.
- 17:50Speaker 2: So if you get a misspelling in the DNA, you
- 17:52Speaker 2: make a mutation in the protein and the protein may
- 17:56Speaker 2: function improperly, which can happen, And that that was their
- 18:01Speaker 2: hypothesis that they took for years. They call it the
- 18:05Speaker 2: gene theory of mutation theory of cancer. That they are
- 18:08Speaker 2: mutant genes and that percinogens are things that mutate genes.
- 18:15Speaker 2: That was their hypothesis, and then they just look for
- 18:19Speaker 2: the particular genes. They look for thousands of them, they
- 18:22Speaker 2: look through the whole genome, and it turns out for
- 18:27Speaker 2: ten years now public doesn't know this, but it's in
- 18:29Speaker 2: the scientific literature. I keep up with it. Obviously it's
- 18:32Speaker 2: easy for me to do. But these gene people have
- 18:35Speaker 2: known for ten years. We've known a lot of people
- 18:38Speaker 2: have known for a lot longer. But I'm talking about
- 18:39Speaker 2: the pharmaceutical people and the academics. People have known for
- 18:44Speaker 2: at least ten years. Gene mutations do not cause cancer,
- 18:49Speaker 2: and they've been although they still publish about these gene mutations.
- 18:54Speaker 2: They still all their literature. They put it in there,
- 18:56Speaker 2: believe it or not. They're even looking at chromosomes these days,
- 18:59Speaker 2: you know, trying to link the you know, the genes
- 19:02Speaker 2: in this chromosome are the problem and the public doesn't
- 19:06Speaker 2: know about. So that's why I wrote this book. One
- 19:08Speaker 2: of the reasons that I wrote my book was to
- 19:11Speaker 2: tell this long.
- 19:12Speaker 1: Story, the outsiders advantage. Say that again, the outsiders advantage.
- 19:18Speaker 2: Yeah, that's my book. See, I should be promoting my
- 19:20Speaker 2: book shit, the Outsider's advantage of personal odyssey in the
- 19:25Speaker 2: essence of Cancer, And I cover this long story all
- 19:29Speaker 2: the way through because it's not just about cancer. It's
- 19:33Speaker 2: about the industry, the our healthcare system, the whole thing,
- 19:38Speaker 2: all the way from government funding and control of pharmaceutical company,
- 19:42Speaker 2: of the trillion dollar industries and cancer and everything else
- 19:45Speaker 2: that they're that they're working on. And they're based on molecules.
- 19:48Speaker 2: Like I said, they're easy to do, they're patentable, and
- 19:52Speaker 2: so they just keep pushing this, keep pushing it, pushing it,
- 19:55Speaker 2: pushing it. And of course that was a peer review.
- 19:58Speaker 2: If somebody tries to publish a paper that doesn't say
- 20:02Speaker 2: any doesn't mention any of the Uncle Jeens, you know,
- 20:05Speaker 2: or anything like that, they talking about chromosome get published,
- 20:09Speaker 2: you know, and Peter and I are not cited anymore.
- 20:13Speaker 2: You know. There was a little over one thousand publications
- 20:18Speaker 2: I looked at recently since about two thousand on cancer,
- 20:24Speaker 2: and I looked for to mention chromosomes. They mentioned any
- 20:30Speaker 2: play about that. Many more papers than a thousand over
- 20:32Speaker 2: that period, but the ones that mentioned chromosomes in anyployee,
- 20:37Speaker 2: I found two or three that actually cite Peter in me.
- 20:41Speaker 2: All right, now, that is normally, you know, here is
- 20:46Speaker 2: considered scientific misconduct not to cite the pertinent literature. But
- 20:50Speaker 2: they're still keeping our names out of it, totally out
- 20:55Speaker 2: of it. And the other people you know that worked
- 20:59Speaker 2: on it, they keep their names out of it. That's
- 21:01Speaker 2: what we're still going through right now. And my book
- 21:05Speaker 2: explains that history and why that's still going on to
- 21:08Speaker 2: this day. And I wanted the Pope people to know
- 21:12Speaker 2: that and why things aren't going anywhere. I'll give you
- 21:16Speaker 2: a chance, asked me some questions.
- 21:17Speaker 1: How about, Well, you covered a lot of ground, and
- 21:21Speaker 1: I kind of want to go back to the age
- 21:23Speaker 1: thing and then we'll come then we'll return to cancer,
- 21:26Speaker 1: because that's where you started when you were working in
- 21:32Speaker 1: the eighties. Fauci also came into his position of power, didn't.
- 21:37Speaker 2: He Yeah, he was. In November of nineteen eighty nineteen
- 21:42Speaker 2: eighty four eighty seven, nineteen eighty seven, Fauchi was made
- 21:47Speaker 2: head of Department of NIAID National Institutes of Allergy and
- 21:52Speaker 2: Infectious Diseases and his job I didn't know it at
- 21:56Speaker 2: that time. I know it now. He was brought in
- 21:58Speaker 2: that position to turn non infectious diseases and infection I'm sorry,
- 22:05Speaker 2: non infectious diseases and non diseases into AIDS. That was
- 22:10Speaker 2: his job and he'd been doing that now for forty years.
- 22:16Speaker 1: I guess fraudulent from the start.
- 22:18Speaker 2: Yeah, from the absolutely from the very beginning, from the
- 22:21Speaker 2: eighties until the day he retired and left. All right,
- 22:25Speaker 2: he had he came up with age AIDS really hooked,
- 22:28Speaker 2: getting a deep and Nity greedy on that in a moment.
- 22:31Speaker 2: But after that he had the first Stars and the
- 22:34Speaker 2: Merseyseeke of the Ebola, you know, and then the second
- 22:37Speaker 2: Stars and all that. They're all bogus. They're all fantasy,
- 22:40Speaker 2: all fiction. There's no evidence for any of those things.
- 22:43Speaker 2: I go back to the age thing here really really quick,
- 22:46Speaker 2: because everything that they were doing in AIDS, they did
- 22:50Speaker 2: it on steroids. To use a metaphor for everything that
- 22:53Speaker 2: followed from that, Antony what was name Bob Gallo, you know,
- 23:01Speaker 2: who supposedly discovered the.
- 23:02Speaker 1: Cause of with with Luke Montaigne.
- 23:06Speaker 2: Luke Monte. Get back to Luke monteue, Well, I'll start
- 23:08Speaker 2: off with Luke Monte. Luke Montaigner had taken some tissues
- 23:13Speaker 2: from AIDS patients, but he could not isolate viruses. He
- 23:16Speaker 2: was not capable of doing that at the time. Certainly
- 23:19Speaker 2: couldn't find any viruses in there. But he knew about
- 23:23Speaker 2: Robert Gallo, I mean, the guy who's been working with
- 23:25Speaker 2: viruses for a long time, that's his thing. So he
- 23:29Speaker 2: sent the tissues from these AIDS patients to Robert Gallo
- 23:34Speaker 2: to see if he could find the virus in there.
- 23:36Speaker 2: Well he didn't. He did not find the virus in there.
- 23:40Speaker 2: In fact, I got the literature on this stuff. So
- 23:43Speaker 2: he couldn't find any virus. So what he did was
- 23:46Speaker 2: he used the same techniques that he used for his
- 23:48Speaker 2: other HTLV his HTLV one HTLV two. There were retroviruses
- 23:55Speaker 2: that he came up with in his laboratory and he
- 23:59Speaker 2: used laboratory to techniques to make these sort of pseudo viruses,
- 24:04Speaker 2: you know, And so he he did the same thing
- 24:09Speaker 2: with Montagner's sample. He could not culture any virus out
- 24:13Speaker 2: of there. So he took a sample of that tissue
- 24:17Speaker 2: and he gave them and then he you know, separated
- 24:19Speaker 2: the cells and cultured the cells, and he stressed the
- 24:22Speaker 2: cells like he did with his HTOV one in HTLV two,
- 24:26Speaker 2: such the cells started getting, you know, really toxic and
- 24:30Speaker 2: they were just trying to survive, and then they would
- 24:33Speaker 2: produce these little mollic these little organelles, they call them
- 24:36Speaker 2: exosomes that leaves leave the cells, and they looked like viruses.
- 24:41Speaker 2: They have the same little structure, and they have the
- 24:45Speaker 2: same dimensions and everything, and all of his htilvs were bogus.
- 24:50Speaker 2: He did them all the same way, and so he
- 24:53Speaker 2: took that did the same thing with Montigner's cells. It
- 25:00Speaker 2: made these exosomes that eventually was called He called it
- 25:04Speaker 2: HTLV three because he did the exact same way that
- 25:07Speaker 2: he got the other ones with. But then they changed
- 25:10Speaker 2: the name to HIV for human immuno deficiency virus, you know.
- 25:15Speaker 2: And he didn't attribute any of this to Luke Montagne, see,
- 25:21Speaker 2: and then Luke Montagne knew what was going on. So
- 25:24Speaker 2: there was this big legal battle, and I don't want
- 25:26Speaker 2: to get in all those discussions between the two. Luke
- 25:28Speaker 2: Montaigne eventually prevailed and Robert Gallo was tried. It wasn't
- 25:35Speaker 2: like a legal trial, but sort of like an academic
- 25:38Speaker 2: trial through the NIH something like that. I don't know
- 25:41Speaker 2: the details. And he was found guilty of scientific misconduct,
- 25:46Speaker 2: lying all that kind of stuff, all right, But the
- 25:50Speaker 2: government could not allow him to be found guilty, so
- 25:56Speaker 2: they were going to retry him. And you can figure
- 25:59Speaker 2: out what was going to go there. The people that
- 26:01Speaker 2: found him guilty were not going to retry, and they
- 26:04Speaker 2: realized the government is just going to come back in
- 26:05Speaker 2: and do the same thing. But it was public knowledge
- 26:09Speaker 2: that he'd been found guilty the first time around, so
- 26:12Speaker 2: they couldn't have the guy who discovered HIV being convicted
- 26:18Speaker 2: of something, you know, and lied and all that. So
- 26:20Speaker 2: they had to get him out and get him totally
- 26:22Speaker 2: out of the picture. So they moved him out of
- 26:25Speaker 2: the NIAI D National Institute's Allergy Infectious Diseases and had
- 26:29Speaker 2: him in this comfortable, nice, little big place where he
- 26:32Speaker 2: was not involved in the government anymore. And he just
- 26:36Speaker 2: stayed over there and he basically was invisible. Like that's
- 26:41Speaker 2: how the government does everything. They take stuff they don't
- 26:45Speaker 2: want the public to know and make get invisible, whether
- 26:48Speaker 2: it's scientific understandings, whether there's people that are doing wrong things,
- 26:53Speaker 2: and you know, recently though decades later then it became
- 26:57Speaker 2: very very public. Louke Montage was one. Ultimately all right,
- 27:02Speaker 2: now I'm going off on these tangents. Where would you
- 27:04Speaker 2: like me to go with that?
- 27:05Speaker 1: Well, just before we go any further, because you know
- 27:08Speaker 1: that the pushback will come and that is this is
- 27:12Speaker 1: all based on the assumptions that viruses exist or can
- 27:16Speaker 1: be isolated.
- 27:17Speaker 2: Yeah. Yeah, But the real key here is that I
- 27:22Speaker 2: stay away from that general question. I'm very specific. You know,
- 27:27Speaker 2: this virus, what's the evidence for that? You know, it
- 27:30Speaker 2: turns out there was no polio virus. You know, that
- 27:33Speaker 2: was totally fraught. That was a toxicological problem as well
- 27:37Speaker 2: documented now, and so I looked into each one. That's
- 27:41Speaker 2: what I did. There was no HIV virus. You say,
- 27:44Speaker 2: there's no stars Kobe two virus. I don't. I don't
- 27:48Speaker 2: want to say there's no such thing this virus is
- 27:50Speaker 2: because frankly, I don't care. The important thing is the
- 27:53Speaker 2: ones that are claimed. You know, what's the evidence for
- 27:56Speaker 2: this one and that one?
- 27:58Speaker 1: You know, and I think that's I think that's scientific.
- 28:01Speaker 2: That is scientific. And I tell you I've looked it up.
- 28:04Speaker 2: You know, there's no ebola virus. I did a big
- 28:08Speaker 2: dive into that. You know, people asked me to look
- 28:11Speaker 2: in these things, and the I just tell you just
- 28:13Speaker 2: a little bit bit about the really short thing about ebola.
- 28:17Speaker 2: One of the things that was publicised, it wasn't publicized,
- 28:20Speaker 2: but it was documented. You know, they had all these
- 28:22Speaker 2: wars going on in the Congo, always fighting in the Congo,
- 28:25Speaker 2: and the Congo is rich and resources and have lots
- 28:28Speaker 2: of gold mines and stuff like that. So one I
- 28:32Speaker 2: don't know which faction it was, but one of them
- 28:35Speaker 2: won and chased off the other people in this gold mine,
- 28:38Speaker 2: which was closed. I mean, nobody's working there because of
- 28:41Speaker 2: the war and because of the gold mine. Somebody, these guys,
- 28:45Speaker 2: the warriors, went into the mind to get some gold
- 28:48Speaker 2: if they could get it, you know. And the problem
- 28:52Speaker 2: with with it, turns out is that gold is chemically
- 28:57Speaker 2: non reactive. So a lot of the things they used
- 28:59Speaker 2: to separate gold from all the other stuff to clean
- 29:02Speaker 2: it out down there, and she used all of these
- 29:05Speaker 2: very very toxic and corrosive chemicals that just dissolve everything
- 29:10Speaker 2: and leaves the gold, you know, you can find it. Unfortunately,
- 29:15Speaker 2: those things are very very toxic, and these guys just
- 29:18Speaker 2: by inhaling it the order and they came out of
- 29:21Speaker 2: the gold mine. And these guys got sick and died
- 29:24Speaker 2: really fast. But only the guys that went down into
- 29:27Speaker 2: the gold the gold mine, you see, And that's just
- 29:31Speaker 2: an I looked at that and all of the other
- 29:34Speaker 2: so coal like the swine flu and all these other
- 29:37Speaker 2: sorts of things. Most of them they come they started
- 29:40Speaker 2: like in Africa or some other place where Americans are
- 29:43Speaker 2: don't care about and nobody digs down and looks into it.
- 29:46Speaker 2: You know, in the United States, other people do. That's
- 29:48Speaker 2: why I know about it, that people publish this stuff,
- 29:50Speaker 2: but you got to dig down into it and find it.
- 29:53Speaker 1: So David, Okay, So going back to HIV in the
- 29:56Speaker 1: late eighties when it was so to speak quote unquote
- 30:02Speaker 1: discovered amongst the gay community. At the same time, poor
- 30:09Speaker 1: black Africans were being labeled as HIV positive.
- 30:14Speaker 2: Oh lord, I mean they were just it was all
- 30:18Speaker 2: a fraud. Everything was a fraud, the chemicals. Let me
- 30:25Speaker 2: go back, first of all with sexual stuff, because the
- 30:29Speaker 2: stuff that I that I have can easily explain. Let
- 30:31Speaker 2: me start with that. The easy, easy stuff is they
- 30:36Speaker 2: took thirty some odd nearly thirty diseases and non diseases
- 30:42Speaker 2: before AIDS, and then if you were HIV positive, they
- 30:46Speaker 2: changed the definition of those things and they became AIDS.
- 30:50Speaker 2: You see, by definition, that's what Fauci had been doing
- 30:54Speaker 2: his whole forty years. He takes it like the flu
- 30:57Speaker 2: the symptoms of the flu in COVID nineteen or on
- 31:00Speaker 2: the CDC's website. Guess what, There was no flutcases in
- 31:04Speaker 2: twenty twenty United States, you know, and Fauci had did
- 31:11Speaker 2: that his whole career. He would take these things, you know,
- 31:15Speaker 2: and they keep adding and women refuse to get AIDS.
- 31:19Speaker 2: So in nineteen ninety three, I believe it was the
- 31:21Speaker 2: CDC added cervical cancer to the ages defining diseases. If
- 31:26Speaker 2: you're HIV positive, all right, But as late as nineteen
- 31:29Speaker 2: ninety seven, only one percent of the age cases were
- 31:32Speaker 2: cervical cancer. So I think, you know, they've been playing
- 31:35Speaker 2: this game for.
- 31:36Speaker 1: Decades, and TV's a big one in Africa.
- 31:40Speaker 2: Yeah, TV, that's right, Africa. I looked at it and
- 31:43Speaker 2: I published this, and I think I put it in
- 31:46Speaker 2: my book even it's all around. Yeah, I'm pretty sure
- 31:50Speaker 2: I did. I did have my book. You know. They
- 31:54Speaker 2: claimed the AIDS came from Africa, you know, and they
- 31:57Speaker 2: made all these lies about how many people like when
- 32:00Speaker 2: Taboa Becky was president, that died under his presidency from
- 32:05Speaker 2: AIDS and everything. And I have documented the increase, the
- 32:09Speaker 2: massive population increased during the whole period of AIDS and
- 32:13Speaker 2: after AIDS in sub Saharan Africa, you know, I mean
- 32:17Speaker 2: they went from like, you know, double the population of
- 32:24Speaker 2: the United States. That's how many you know, like sub
- 32:27Speaker 2: Saharan Africa they would they would went over to a billion.
- 32:31Speaker 2: Other's over a billion people in sub Saharan Africa, you know,
- 32:34Speaker 2: and there were roughly around I forget what it was
- 32:38Speaker 2: around the population of the United States and South Africa
- 32:42Speaker 2: was lower of course that particular state country. And it
- 32:47Speaker 2: was a population explosion like three percent or something like that,
- 32:51Speaker 2: you know, you know, there was no population declined. It
- 32:56Speaker 2: was a massive explosion. Everything they said about AIDS and
- 33:00Speaker 2: all the other things that were going on in Africa,
- 33:03Speaker 2: they had this popul You cannot have these population explosions
- 33:06Speaker 2: going on if all these other things are true.
- 33:08Speaker 1: Yeah, So basically what you're saying is that they were
- 33:11Speaker 1: they were just labeling various illnesses as AIDS.
- 33:16Speaker 2: Yes, absolutely, And people don't know this. It's also in
- 33:19Speaker 2: my book. There are two different definitions of AIDS. One
- 33:23Speaker 2: for the industrial part of the world, where HIV is
- 33:25Speaker 2: part of the definition, and they have like thirty some
- 33:27Speaker 2: odd diseases that the Westerners get. If your HIV positive
- 33:31Speaker 2: your AIDS and Africa HIV is not have been part
- 33:34Speaker 2: of the definition of ADS. It's fever, diarrhea, persistent cough,
- 33:38Speaker 2: weight loss in TB. Those are the diseases of poverty
- 33:41Speaker 2: and malnutrition. You know, they're the standard things that always
- 33:45Speaker 2: happen to the people down there. So uh, you know,
- 33:49Speaker 2: they've relabeled it, just like Robert Gallo, I mean, Fauci
- 33:53Speaker 2: relabeled the Western Diseases is AIDS well. The World Health
- 33:59Speaker 2: Organs met in Bangui, the capital of Central African Republic,
- 34:05Speaker 2: in nineteen eighty five. I think it was they came
- 34:08Speaker 2: up with the definition made in Africa and those diseases
- 34:11Speaker 2: poverty and malnutrition, and they had to have an AIDS
- 34:14Speaker 2: epidemic in Africa because that's where the United States said
- 34:17Speaker 2: it came from. That's why they had in nineteen eighty five.
- 34:21Speaker 2: They had to come up with that definition really really quick.
- 34:25Speaker 2: But you said, because its Africa and America is not
- 34:28Speaker 2: paying attention, you can lie or you want to about Africa.
- 34:31Speaker 2: I bets you most everything that is in mainstream media
- 34:35Speaker 2: about Africa is a lie. That'd be my guest, because
- 34:38Speaker 2: everything they talk about diseases is a lie.
- 34:42Speaker 1: So this matter is to me though, because I live
- 34:44Speaker 1: in South Africa. South Africa was pretty much the epicenter
- 34:47Speaker 1: of AIDS internationally, and you have a history also with
- 34:52Speaker 1: South Africa and president, former President Tavin Beaky who was
- 34:56Speaker 1: removed because of his position on HIV AIDS.
- 34:59Speaker 2: Where right, And I actually I was on this one
- 35:03Speaker 2: of the members of his AGE Advisory Panel. I think
- 35:06Speaker 2: it was two thousand and one.
- 35:09Speaker 1: Yeah, I've got the I've actually got the AGE Report
- 35:11Speaker 1: in which, by the way, I think on page fifteen
- 35:14Speaker 1: it recommends against PC artists.
- 35:17Speaker 2: Yes, I know, my cat's buggin and she wants to
- 35:23Speaker 2: be part of this conversation.
- 35:25Speaker 1: And that was in two thousand and one.
- 35:27Speaker 2: Yeah, I know, and uh, you know, and they had
- 35:31Speaker 2: all these campaigns. There was a Treatment Action Campaign THC
- 35:36Speaker 2: was well funded by probably yeah, by by a lot
- 35:40Speaker 2: of different people, and they were anti a banky and
- 35:44Speaker 2: I put that in my book too, about what was
- 35:46Speaker 2: going on there and oh this God, there's so many
- 35:50Speaker 2: crazy things, crazy crazy things. Uh. And there was this
- 35:55Speaker 2: huge political push and I guarantee the United States was
- 35:58Speaker 2: funding a lot of this stuff and trying to keep
- 36:02Speaker 2: this thing going and try and put pressure on taboone
- 36:05Speaker 2: baking because they destroyed his aid's advisory panel. He went there,
- 36:09Speaker 2: you know, had two thirds of the panel where mainstream
- 36:12Speaker 2: AIDS people and then one third were critics like me,
- 36:17Speaker 2: Peter Boozberg and other people, and they never allowed it
- 36:21Speaker 2: to happen. We could not have a discussion. I put
- 36:24Speaker 2: this in my book too, where it was I think
- 36:27Speaker 2: a three day meeting and we were just about ready
- 36:31Speaker 2: to get this thing started when three black Americans, very
- 36:37Speaker 2: dark black Southern Africa is sort of a brown, not
- 36:40Speaker 2: a black, but three very dark black Americans, all dressed
- 36:44Speaker 2: the same, very dark suits, came in, no names, no nothing.
- 36:47Speaker 2: They sat down and the whole thing almost came tumbling
- 36:52Speaker 2: down at that point because the people, like the critics
- 36:56Speaker 2: of Becky's people, the government wanted to know who these
- 36:58Speaker 2: people were, you know, and and uh so they toned
- 37:05Speaker 2: it down because eventually somebody from a Becky's office was
- 37:09Speaker 2: sent down there and said, uh that these guys at
- 37:13Speaker 2: the government President of United States asked that these guys
- 37:17Speaker 2: be there, sir Mike. Mike personal feeling is that these
- 37:21Speaker 2: very uh big guys at somber guys was no I
- 37:26Speaker 2: d no name tags or anything. I think they were
- 37:29Speaker 2: there to be a very big sign of keep your
- 37:31Speaker 2: mouth shut, because that's exactly what happened, and especially the mainstreamers,
- 37:38Speaker 2: because they knew they couldn't keep us shut, our mouth shut,
- 37:41Speaker 2: you know, the critics of what was going on, and
- 37:44Speaker 2: uh so uh that we started to go. You know,
- 37:49Speaker 2: Peter Dewsburg was going to give the very first presentation
- 37:53Speaker 2: and one of the mainstreamers on the panel said, no, no, no,
- 37:56Speaker 2: no presentation of data. Can you believe that? You know,
- 38:00Speaker 2: now the public, American public doesn't know this if they'd
- 38:03Speaker 2: just seen that, and in fact that one of the
- 38:06Speaker 2: local television stations had permission they wanted to present this
- 38:12Speaker 2: live to the people of South Africa. And the president
- 38:15Speaker 2: said fine, the government said fine. The mainstreamer said, no,
- 38:18Speaker 2: can't do this.
- 38:19Speaker 1: I've actually got I've actually got a video portion from
- 38:23Speaker 1: that event and you can see it's a complete shambles.
- 38:26Speaker 2: Yeah, yeah, there were some the government said the government
- 38:30Speaker 2: was there themselves, were videoing the whole thing the whole time.
- 38:35Speaker 2: In fact, we were told, the panelists members were told
- 38:37Speaker 2: that one day that that was going to be made
- 38:39Speaker 2: available to the people of South Africa. Of course, that
- 38:41Speaker 2: has not happened.
- 38:42Speaker 1: What you're arguing and have argued, is that HIV does
- 38:49Speaker 1: not cause AIDS, and even if HIV did exist, it
- 38:51Speaker 1: doesn't cause AIDS because AIDS is just a collection of
- 38:55Speaker 1: illnesses and there's no collective agreement internationally on what it
- 38:59Speaker 1: even means.
- 39:00Speaker 2: It doesn't behave like a contagious infectious disease at all.
- 39:03Speaker 2: And get into that. Let me tell you this all
- 39:07Speaker 2: you have to do, and I have them the package
- 39:09Speaker 2: inserts to come with all the HIV tests, sorrows and
- 39:13Speaker 2: other stuff all the way down that it says that
- 39:16Speaker 2: for example, the antibody test, HIV antibody test, also the
- 39:20Speaker 2: pc R, but the HIV antibody tests to go in there.
- 39:24Speaker 2: There's big long package insert that comes with it, and
- 39:26Speaker 2: you go down there and you look at particulars so
- 39:29Speaker 2: you can see how effective it is and everything, and
- 39:31Speaker 2: they say specifically in there they had no authentic reference
- 39:35Speaker 2: sample of HIV to validate the test. That's not exact quote.
- 39:41Speaker 2: I don't remember the exact quote, but that's what they say,
- 39:43Speaker 2: and I have it. I use it a lot of
- 39:45Speaker 2: presentations and even legal cases show it to people, and
- 39:49Speaker 2: we want a number of cases just by showing the
- 39:52Speaker 2: package inserts to come with the HIV antibody test, and
- 39:56Speaker 2: it says that says they had no way to validate
- 40:00Speaker 2: the test. They had no HIV to compare the test against.
- 40:05Speaker 2: That they assumed, they used the word assume that one
- 40:08Speaker 2: hundred percent of the people who were positive were infected
- 40:12Speaker 2: with HIV. And if they were looking for they were
- 40:15Speaker 2: looking for HIV. They were looking for your antibodies that react,
- 40:18Speaker 2: you know, stick to HIV, all right. That happens a lot.
- 40:22Speaker 2: And I can even go that's even tight trated, that's
- 40:25Speaker 2: even made to produce a certain number of HIV positive people.
- 40:29Speaker 2: So they had no way to validate any positive result,
- 40:35Speaker 2: which also means they had no way to validate a
- 40:37Speaker 2: negative result. But with the positive, the people the hundred
- 40:42Speaker 2: they assumed that, you know, there were that these people
- 40:45Speaker 2: that were positive, they were assumed all one hundred percent
- 40:47Speaker 2: of them they had the disease, were infected, all right,
- 40:52Speaker 2: And they had something like ninety nine points something false negative.
- 40:58Speaker 2: And that was I forget get how they did that.
- 41:01Speaker 2: They had no way, no way to validate it, but
- 41:03Speaker 2: I think they had They had some I can't remember
- 41:06Speaker 2: what it was, but it's in the package in serve. Anyway,
- 41:09Speaker 2: they had no way to validate the test. They had
- 41:12Speaker 2: no way to do that with the pc R, They
- 41:14Speaker 2: had no way to do that with the SARS, the
- 41:16Speaker 2: murders the beak of the ebola or the SARS Kobe two.
- 41:21Speaker 2: And it says so in the CDC on their website
- 41:24Speaker 2: to this day says there was no uh. I forget
- 41:28Speaker 2: the words they used, No uh, sars kobe Yeah, sorry,
- 41:34Speaker 2: no not. What's it called the virus itself? Not SARS
- 41:37Speaker 2: kobe two. Yeah, I guess it was. Anyway, there was
- 41:40Speaker 2: no virus available for them to validate their antibody tests.
- 41:46Speaker 1: So what are they so? What are they using? They're
- 41:48Speaker 1: just making it up, making it up.
- 41:51Speaker 2: In fact, the I tell you about these tests, the tests,
- 41:55Speaker 2: you know, I was in the pharmaceutical industry and the
- 41:57Speaker 2: diagnostics division, so I understand procedure. Normally, when you take
- 42:02Speaker 2: a patient sample, you want to keep it as concentrated
- 42:05Speaker 2: as possible. In other words, you don't want to loot
- 42:07Speaker 2: out any poison or path of gener or whatever like that, bacteria, anything,
- 42:12Speaker 2: and so you take a sample either use it neat
- 42:14Speaker 2: like a swab from your mouth, or if you have
- 42:17Speaker 2: to put it like in a dish. You just dilute
- 42:19Speaker 2: it with buffer or something, or just a small amount
- 42:24Speaker 2: before you actually do the test, so that you can
- 42:28Speaker 2: make sure you find this thing. Well, the package inserts
- 42:32Speaker 2: direct you you have to dilute the blood sample four
- 42:36Speaker 2: hundredfold before you do the test. Typically it's like two folds,
- 42:42Speaker 2: maybe four fold, but it's four hundredfold all right now.
- 42:48Speaker 2: And I tell I think this was a titration. What
- 42:51Speaker 2: do I mean by titration? You set the rules based
- 42:55Speaker 2: on what the outcome you want to get. Why was
- 42:58Speaker 2: it four hundred not two hundred or three hundred? You know?
- 43:01Speaker 2: So they wanted to know. And all you got to
- 43:04Speaker 2: do is look at my website. I have it on
- 43:06Speaker 2: my website under AIDS that the number, you know, infectious
- 43:10Speaker 2: diseases come up really fast like a flu or something,
- 43:14Speaker 2: and then go down in months. You know. That's how
- 43:16Speaker 2: they always do. They come up, they go away, come up,
- 43:19Speaker 2: they go away. Well for the twenty thirty years, I
- 43:24Speaker 2: stopped looking. After twenty years, the government numbers of AIDS
- 43:31Speaker 2: patients people living with HIV put it this way, people
- 43:34Speaker 2: living with HIV in the United States was one million
- 43:38Speaker 2: plus a minus one hundred thousand. I have a little
- 43:41Speaker 2: graph of it on my website under AIDS. All right,
- 43:44Speaker 2: there's no infectious disease in the world. It does that,
- 43:47Speaker 2: you know, it stays constant like that, But AIDS does
- 43:51Speaker 2: that one million number has been constant since since nineteen
- 43:55Speaker 2: eighty four or eighty five, you know, And it goes
- 43:58Speaker 2: up a little bit, goes down.
- 43:59Speaker 1: A little bit, right, hold on Conday, use account all
- 44:02Speaker 1: even say yes, but it's because of ROVs.
- 44:06Speaker 2: Ar vs at your retrorail. No, it should go down
- 44:11Speaker 2: if it was going to do any if any therapy
- 44:13Speaker 2: was working, it should go down. It's just stayed constant.
- 44:18Speaker 2: Has nothing to do with the therapies. It has to
- 44:20Speaker 2: do with the tests, you see. So my theory hypothesis
- 44:25Speaker 2: was that's where that four hundred full thing came from,
- 44:29Speaker 2: and that's still in there to do it so that
- 44:31Speaker 2: maintains this constant number if you're going to do that.
- 44:36Speaker 2: The other thing is like Asians have the lowest. It's
- 44:39Speaker 2: a racial thing. Asians have the lowest anybody level constant
- 44:46Speaker 2: anybody level for HIV Africans, people of black Africans have
- 44:52Speaker 2: the highest, and Westerners are sort of intermediate in there.
- 44:58Speaker 2: But isn't it.
- 44:59Speaker 1: Isn't it interesting? Sorry for interrupting that. Former South African
- 45:02Speaker 1: president Tabin Bak he said that AIDS is a disease
- 45:06Speaker 1: of poverty.
- 45:09Speaker 2: Yes, but you want to get into that right now,
- 45:16Speaker 2: not really a disease of poverty. I mean, he was
- 45:20Speaker 2: a president and he saw poverty, and he saw the
- 45:22Speaker 2: sick people. You know, he attached the word AIDS to it.
- 45:27Speaker 2: You know, number these people are sick. Yeah, yeah, you
- 45:30Speaker 2: know they're the ones that get the age defining diseases
- 45:33Speaker 2: in Africa, fever, diarrhea, persistent calfweight loss in TV. Those
- 45:36Speaker 2: are the poor people, all right. So in a way,
- 45:40Speaker 2: if you're changing the name of those diseases to AIDS,
- 45:43Speaker 2: it is a disease of poverty. But I mean you
- 45:47Speaker 2: played these games, you know, you go back and forth.
- 45:50Speaker 1: I mentioned VS aero VS. If I remember correct. He
- 45:53Speaker 1: started out.
- 45:54Speaker 2: Viral drugs for people.
- 45:56Speaker 1: Yes, they started out as a cancer therapy, a chemotherapy
- 46:02Speaker 1: in the nineteen eighties. So there's an interesting link to cancer.
- 46:05Speaker 2: Yes. So AZT was the first.
- 46:08Speaker 1: One and that was given to Freddy Mercury.
- 46:12Speaker 2: Freddy Mercury, Yeah, he was given me, Yeah.
- 46:15Speaker 1: He was he was a singer of Queen who supposedly
- 46:18Speaker 1: died of aides, but Judy Mikowitz argues that he died
- 46:23Speaker 1: of AZAT. He was given fifteen hundred minigrams per day.
- 46:27Speaker 2: Oh Lord, that's horrible. Yeah, John Lawrence, and he's a journalist.
- 46:32Speaker 2: He's no longer with us anymore. He told me personally,
- 46:35Speaker 2: and he's written about this too, but he told me personally.
- 46:37Speaker 2: AZT in the late eighties, early nineties. Still three hundred
- 46:41Speaker 2: and thirty thousand gay men in the United States and
- 46:44Speaker 2: it's still az T. Let me go into the AZT story.
- 46:48Speaker 2: Zitothimony has lots of other different names. It was developed
- 46:52Speaker 2: in the nineteen sixties as chemotherapy for cancer. You know,
- 46:57Speaker 2: is very very toxic. It's so toxic that they never
- 47:02Speaker 2: even bothered to patent it. Now, think about that pharmaceutical company.
- 47:05Speaker 2: Guys developing things, they patent everything. It was so toxic
- 47:10Speaker 2: they didn't even patent it. That's why they could use it.
- 47:13Speaker 2: It was not patented, but they wanted but they for cancer.
- 47:17Speaker 2: But they eventually, I think they did patent it for
- 47:19Speaker 2: AIDS and and the bottle of it. Peter Deusburg ordered
- 47:26Speaker 2: a bottle of AZT and he showed me the label,
- 47:28Speaker 2: and I even have it on my website that if
- 47:31Speaker 2: you're a scientist, a researcher and you get a bottle
- 47:33Speaker 2: of it, comes to skulling crossbones on on on the label,
- 47:37Speaker 2: you know, and if you use it, go see it.
- 47:41Speaker 2: You know, if you get contact with it, go see
- 47:44Speaker 2: a doctor or something, take care of it real quick.
- 47:46Speaker 2: And they tell the problems that it could cause, you know,
- 47:49Speaker 2: skulling crossbones. They didn't put that on the on the
- 47:51Speaker 2: AZT bottle. They gave these HIV positive gay guys or
- 47:55Speaker 2: HIV and they killed, like I say, you know, over
- 48:00Speaker 2: hundreds of thousands, you know, and who knows if it's
- 48:03Speaker 2: in the millions. I have no idea what the other
- 48:06Speaker 2: things do. That's just one drug, one drug, AZD. Yeah,
- 48:09Speaker 2: So I don't know what else to say about AZD
- 48:14Speaker 2: other than they knew.
- 48:15Speaker 1: It was lethal cancer. You were making the point earlier
- 48:20Speaker 1: that then it's not genetic. Does that mean it's metabolical? Environmental?
- 48:27Speaker 2: Oh, it's so, what causes it? Carcinogens? That's easy word
- 48:31Speaker 2: to say, you know, but what are carcinogens? I think
- 48:34Speaker 2: about asbestos, a lot of chemicals that cigarette smoke these
- 48:42Speaker 2: are things, and what do they do. These carcinogens disrupt
- 48:47Speaker 2: the separation of the DNA during cell division, the chromosomes
- 48:51Speaker 2: during cell division. Every carcinogen that has ever been evaluated
- 48:56Speaker 2: as a carcentergen blocks the balance separation of chromosomes. And
- 49:02Speaker 2: it's and that's that's what that's what gets it started.
- 49:06Speaker 2: It could be X rays, you know, when you have
- 49:09Speaker 2: extra Every time you get an X ray, you're disrupting
- 49:11Speaker 2: the cells in your body. That's they screws up with
- 49:14Speaker 2: the separation of chromosome. All carcinogens screwed up with a
- 49:18Speaker 2: balanced separation of chromosomes. And that's how all cancers start.
- 49:23Speaker 2: They all start with an imbalanced number unbalanced number of chromosomes.
- 49:29Speaker 1: But then how do you explain what appears to be
- 49:33Speaker 1: a genetic cancer. Let's say brast cancer and they'll say, well,
- 49:38Speaker 1: my mother had it, and therefore the daughter's likely to
- 49:40Speaker 1: have it.
- 49:41Speaker 2: Yeah, well, you could do this about anything, you know,
- 49:45Speaker 2: if you have a family of smokers, you know, smokes cigarettes,
- 49:49Speaker 2: you know, and you can say, okay, it was your family,
- 49:52Speaker 2: must have been the food you're eating, it must have
- 49:54Speaker 2: been the air you're breathing. But they don't really say
- 49:57Speaker 2: what about the cigarettes you were smoking, you know? Or
- 50:00Speaker 2: what about the glac estate that you're working with? You know?
- 50:04Speaker 2: Uh and uh. And also it's the region. You can
- 50:09Speaker 2: make all these associations, but they don't prove anything. They're
- 50:13Speaker 2: just the start a hypothesis to look into and when
- 50:17Speaker 2: you look into it, really dig into it, it's not
- 50:21Speaker 2: people really really looked into it. The gene mutation people
- 50:25Speaker 2: have now for decades and they have not found a
- 50:28Speaker 2: single gene mutation, not one. Got I've got this quoted,
- 50:33Speaker 2: you know, and the people have happened in the industry
- 50:36Speaker 2: are open about it now for ten years. There's no
- 50:39Speaker 2: such thing as a cancer causing gene. They haven't found any.
- 50:43Speaker 1: So I had the pleasure of interviewing Thomas Seafeet and
- 50:48Speaker 1: he argues something similar to you. He says that it's
- 50:50Speaker 1: not genetic. He says that it's metabolic and that and
- 50:53Speaker 1: that a keitogenic diet, for example, is quite helpful in
- 50:57Speaker 1: reduced is it. Do you agree with that?
- 50:59Speaker 2: Yeah? The thing that the only disagreement and I've never
- 51:03Speaker 2: even really talked to him, but just some people that
- 51:05Speaker 2: are bringing his point of view. Everything he says about
- 51:09Speaker 2: that the whole thing about cancer and the glycolsis business
- 51:13Speaker 2: and all that, which I totally agree with. What was
- 51:16Speaker 2: Auto Warburg recognized and published on what's now called the
- 51:21Speaker 2: Warburg Effect, I think it was nineteen thirty six or
- 51:24Speaker 2: something like that, where he noticed that the normal energy
- 51:29Speaker 2: source of cells, the cancer cells, are not like normal
- 51:33Speaker 2: healthy cells in humans. In fact, they shut down the
- 51:36Speaker 2: cancer cells shut down the mitochondria that they're the energy
- 51:41Speaker 2: producing factories in our cells. All right, we also have
- 51:44Speaker 2: an ancient fermentation source in our body too. It's called glycolsis.
- 51:51Speaker 2: Glycolosis is what bacterias other organisms do. If you want
- 51:55Speaker 2: to convert sugar into wine or beer or something like that,
- 51:59Speaker 2: or whiskey, you have glycolosis that turns that glucose into ethanol. Well,
- 52:05Speaker 2: the glycolysis. We also have that capacity in our body,
- 52:09Speaker 2: and the cancer cells rely on glycolosis to turn glucose
- 52:15Speaker 2: into energy atp you call it ATP, and it's two
- 52:19Speaker 2: hundred times faster. The glycolysis is two hundred times faster
- 52:23Speaker 2: than the mitochondria. Mitochondria much more efficient. You get much
- 52:27Speaker 2: bigger bangs or your book than you do with glycolosis.
- 52:30Speaker 2: But glycolosi is like a fire hose. It just puts
- 52:32Speaker 2: it out there really really fast. All right. And now
- 52:37Speaker 2: we're getting to the point where I disagree with the
- 52:40Speaker 2: seaphree that when it talks about aniuploidy. My big thing
- 52:46Speaker 2: is all cancer cells are an all cancer c annuploidy
- 52:51Speaker 2: is what causes every aspect, including glycolois, you.
- 52:55Speaker 1: Know, which is that imbalance?
- 52:59Speaker 2: Yes, and se I don't know if Sefford himself because
- 53:03Speaker 2: I haven't communicated with him, but people that know him personally,
- 53:07Speaker 2: you know, I've worked with him, says that the glycolosis
- 53:12Speaker 2: is what causes the annuplad Now, I don't know that
- 53:15Speaker 2: Seffred himself says that, but that's I had a debate
- 53:20Speaker 2: a couple of debates with people on that. And if
- 53:23Speaker 2: that were true, then there should what comes first. You
- 53:27Speaker 2: say that, That's all you gotta do is look at
- 53:28Speaker 2: the earliest stage of the cancer. See what comes first.
- 53:32Speaker 2: The earliest thing in all cancers and pre cancers is annuplating,
- 53:37Speaker 2: no exception, all right, not glycolosis. Glycolosis is a result
- 53:43Speaker 2: of annuplating, and it's very very simple once you see it.
- 53:48Speaker 2: The cancer cells typical cancer cells have seventy percent more
- 53:53Speaker 2: DNA seventy percent on average the range in there, you know,
- 53:57Speaker 2: seventy percent more DNA, except because they have seventy percent
- 54:01Speaker 2: more chromosomes than normal cells, which is the DNA, and
- 54:06Speaker 2: the relative proportions of the DNA to RNA to protein
- 54:12Speaker 2: in a cell are constant. In other words, if you
- 54:15Speaker 2: double the amount of DNA in your cell, you double
- 54:18Speaker 2: the amount of RNA in your cell, you double the
- 54:21Speaker 2: amount of protein. Now you have a nucleus that Tapernicolile
- 54:26Speaker 2: was using to look at. He was looking with a
- 54:27Speaker 2: light microscope. You can see large nucleuses of cancer cells
- 54:32Speaker 2: are much larger than normal cells, and they're abnormal looking,
- 54:35Speaker 2: and that's because they have so many extra chromosomes in there.
- 54:38Speaker 2: And the whole, the cell as a whole, cancer cell
- 54:41Speaker 2: as the whole is shrinking as a whole, But the
- 54:43Speaker 2: nucleus is getting bigger and bigger, and the mitochondria are
- 54:47Speaker 2: the next largest thing compared to the nucleus. So they
- 54:50Speaker 2: can come and go it will, and they do it
- 54:52Speaker 2: all the time. In the healthy cells that mitochondria can
- 54:56Speaker 2: reproduce and they can go away, and they go away
- 54:59Speaker 2: in cancer cells to make room for all the extra stuff.
- 55:03Speaker 2: The protein, the chromosomes is getting very very crowded in there.
- 55:09Speaker 2: But the cell has to have energy, so they can't
- 55:12Speaker 2: rely on the mitochondria because mitochondria can't work in such
- 55:15Speaker 2: a small area, they can't even survive. So they rely
- 55:18Speaker 2: on glycolysis, which two hundred times faster, you see. So
- 55:22Speaker 2: it's the anuploidy that is the cause of the glycolysis.
- 55:28Speaker 2: It needs a source of energy. There's no room for
- 55:31Speaker 2: the mitochondria. That's why the mitochondrias shrivel and start leaving
- 55:37Speaker 2: in the cancer cells, and then glycolysis. It just goes
- 55:41Speaker 2: up ruined fresh. And glycolysis is the achilles heel of
- 55:45Speaker 2: all cancer that I'm aware of, you know, certainly all
- 55:48Speaker 2: solid termbers. I haven't looked into it for the blood cancers,
- 55:53Speaker 2: but probably true there too.
- 55:55Speaker 1: But it is a good idea. So it is a
- 55:56Speaker 1: good idea though to keep your sugar intake low, Yes,
- 56:00Speaker 1: don't write.
- 56:02Speaker 2: Certainly glucose has an absolute requirement for glucose, and that
- 56:06Speaker 2: is the achilles heel of all of all cancer, all right,
- 56:09Speaker 2: And that's what those things like ivermectins and bendazole, some
- 56:12Speaker 2: of these other things. Uh, cancer has so many achilles
- 56:16Speaker 2: heels that glycolysis is one of the biggest ones, you know,
- 56:20Speaker 2: and they've known this for a long long time since
- 56:21Speaker 2: out of Warburg. But it's easy to deal with, you know,
- 56:27Speaker 2: you can do it with these very inexpensive drugs. And
- 56:32Speaker 2: so that's that's basically it. You know. So traumosomes is
- 56:37Speaker 2: what makes all the difference.
- 56:40Speaker 1: How effective is chemotherapy.
- 56:43Speaker 2: Oh, it's very effective at killing people. It's the sixth
- 56:48Speaker 2: leading cause of cancer. So it's very effective at those things. Uh,
- 56:53Speaker 2: it had it has no therapeutic effect at all, benefit
- 56:58Speaker 2: at all. It should all stop immediately all chemotherapy and radiation.
- 57:03Speaker 2: They're totally lethal. They're lethal, they're harmful, they have no
- 57:07Speaker 2: beneficial effects. What all zero? All right, and that's a
- 57:13Speaker 2: very good reason to keep me shut up, you know,
- 57:16Speaker 2: and to keep the other people who want to you know.
- 57:21Speaker 1: But you know that the count response is Ah, but David,
- 57:24Speaker 1: I know somebody who went through chemotherapy and they cancel
- 57:28Speaker 1: went into remission.
- 57:30Speaker 2: Yeah for how long? How long? How long was the remission? Okay,
- 57:39Speaker 2: let me give you the numbers, the current numbers, and
- 57:44Speaker 2: they're going down of people. It's the five year survival rate,
- 57:49Speaker 2: which they keep every year. You know, you can get
- 57:51Speaker 2: the data. The five year survival rate on chemo the
- 57:56Speaker 2: people taking chemo therapy the standard treatments is two to
- 58:00Speaker 2: three percent for five years, two to three percent. All right.
- 58:07Speaker 2: Coli'S toxin, which I haven't talked about yet. We talk
- 58:10Speaker 2: about William Coley a little bit if you want to,
- 58:12Speaker 2: and these other non toxic things, but Coli'S toxin has
- 58:16Speaker 2: his daughter he went around. I'll tell the details about
- 58:19Speaker 2: what it is. At the moment, I should tell the story.
- 58:22Speaker 2: He was using this now for years. He was an
- 58:25Speaker 2: oncologist in New York. He's a physician, and he had
- 58:29Speaker 2: been treating and other people had been using what are
- 58:32Speaker 2: called Coli toxins or mixed bacterial toxins over the decades.
- 58:37Speaker 2: His daughter compiled the data from all over the world
- 58:41Speaker 2: people are using his method, and the five year survival
- 58:46Speaker 2: rate of people taking Coli'S talks and cancer patients is
- 58:49Speaker 2: fifty percent, not two percent, not three percent, fifty percent,
- 58:55Speaker 2: all right. And the only way that I've been able
- 58:59Speaker 2: to find the use of Coli'S toxic in the United
- 59:02Speaker 2: States is if people are simultaneously taking demote therapy. But
- 59:06Speaker 2: if you go to Europe, if you go to Mexico,
- 59:09Speaker 2: they use these non toxic therapies for people, and it's
- 59:14Speaker 2: becoming more popular now. I mean now, the glacolsist thing
- 59:19Speaker 2: now is all the rage. Thank goodness, Finally it's getting
- 59:22Speaker 2: out there. It's been known since nineteen thirty six.
- 59:28Speaker 1: David, this is actually a topic that's way bigger than
- 59:32Speaker 1: one hour, and time is now against us. I'm wondering
- 59:35Speaker 1: if you'd be so kind as to return for a
- 59:39Speaker 1: second conversation so we can unpack some of this even more.
- 59:42Speaker 2: I'd be happy to. I know, it's a long story.
- 59:44Speaker 2: Each one of these stories is a long story.
- 59:48Speaker 1: Yeah, okay, all right, fantastic. Okay, So then for now,
- 59:52Speaker 1: how can my audience follow your work?
- 59:54Speaker 2: You can go to my website. It's David Rasnik dot com.
- 59:59Speaker 2: Has forty year's worth of information on there, and I
- 1:00:03Speaker 2: keep it updated on a regular basis. Some of my
- 1:00:06Speaker 2: books you could get download them from their papers. I've
- 1:00:11Speaker 2: had various different links like to cancer into aids, and
- 1:00:15Speaker 2: I've got tons and tons of information and data. You
- 1:00:18Speaker 2: just to keep going deeper and deeper as you took
- 1:00:21Speaker 2: on these icons and so you can learn about William Coley,
- 1:00:27Speaker 2: Peter Diusburg, the AID stuff, the cancer, all the tests
- 1:00:32Speaker 2: on HIV, those things I was telling you about the
- 1:00:34Speaker 2: information I've got on there, about how bogus are, and
- 1:00:40Speaker 2: lots and lots of stuff, these lots of videos. I've
- 1:00:42Speaker 2: been doing tons of these things even before my book
- 1:00:45Speaker 2: came out, but now it's exhausting me. But I'm not complaining,
- 1:00:50Speaker 2: all right.
- 1:00:51Speaker 1: Well, on that note, to David Reisnick, thank you for
- 1:00:53Speaker 1: joining me in the trenches.
- 1:01:00Speaker 2: Nay erm Haple